

## FORM 7

### **MONTHLY PROGRESS REPORT**

**For January 2019**

Name of Listed Issuer: **Liberty Health Sciences Inc. (formerly, SecureCom Mobile Inc.)** (the "Issuer" or "Company").

Trading Symbol: **LHS**

Number of Outstanding Listed Securities: **345,290,635 common shares**

Date: **February 13, 2019**

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*On January 8<sup>th</sup>, the Company announced that Vic Neufeld and John Cervini were stepping down from the Board of Directors, effective January 31, 2019 and that the Board was continuing its search for two qualified and independent board members. Further, the Company announced that it had retained Miller Thomson LLP as its Canadian legal counsel. Miller Thomson will provide advice on, among other things, Canadian corporate governance practices and securities law compliance matters.*

*On January 21<sup>st</sup>, the company announced the appointment of Ian McKinnon and John Hick to its Board of Directors. Mr. McKinnon assumes the role of Chairman of the Board. Vic Neufeld and John Cervini, who had previously announced they would resign from the Company's Board of Directors as of January 31, 2019, accelerated their resignations to be effective January 18, 2019, and Mr. Hick's and Mr. McKinnon's appointments were both effective as of such date.*

*The Company intends to continue to evaluate strategic avenues for growth including, but not limited to, evaluating targets for expansion in key U.S. states that have approved medical use of marijuana and meet its stringent investment criteria.*

2. Provide a general overview and discussion of the activities of management.

*In Florida, in addition to overseeing the retrofit activities at its Liberty 360° Innovation Campus in Gainesville, management continues to seek potential dispensary sites.*

*In Ohio, management is working with the Company's Ohio joint venture partner, the Schottenstein Group, on the plans to build-out a processing facility as well as a dispensary in Dayton. Both have preliminary start-up dates of April 2019, which remains subject to receipt of required regulatory approvals.*

***In Massachusetts, management is working on developing a strategy to optimize opportunities in connection with adult use of cannabis being now being legal in the state.***

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

***None in the month of January.***

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

***None to report in the month of January.***

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

***None to report in the month of January.***

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

***None to report in the month of January.***

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

***None to report in the month of January.***

8. Describe the acquisition of new customers or loss of customers.

***The Company continues to grow its number of patients as the overall Florida market increases in terms of registered patients and as the Company expands its footprint in the state.***

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

***None in the month of January.***

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

***The Company continues to add personnel in the areas of patient care and product deliveries in the Florida operations as well as dispensaries with the expected opening of additional dispensaries over the next 30-60 days.***

***There were no significant terminations or lay-offs in the month of January.***

11. Report on any labour disputes and resolutions of those disputes if applicable.

***None to report in the month of January.***

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

***None to report in the month of January.***

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

***No new debt to report for the month of January.***

14. Provide details of any securities issued and options or warrants granted.

***A total of 2,802,885 broker warrants were exercised in the month for 2,802,885 shares in the capital of the Company and net proceeds of \$1,749,000.***

***A total of 2,380,000 stock options were granted under the Company's stock option plan in the month, with an exercise price of \$0.96 per share. These options were granted to a combination of directors, consultants and certain employees of the Company.***

15. Provide details of any loans to or by Related Persons.

***None to report in the month of January.***

16. Provide details of any changes in directors, officers or committee members.

***Vic Neufeld and John Cervini resigned from the Board effective January 18<sup>th</sup> and were replaced by Ian McKinnon and John Hick. Mr. McKinnon replaces Vic Neufeld as the Chair of the Board.***

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

***The Issuer experienced difficulty in respect of cross-border travel by certain of its executives and directors in the month of January. The board is exploring potential options to deal with this issue.***

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. To the best of the undersigned's knowledge and belief, as of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that, to the best of the undersigned's knowledge and belief, the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. To the best of the undersigned's knowledge and belief, all of the information in this Form 7 Monthly Progress Report is true.

Dated February 13, 2019.

Rene Gulliver  
Name of Director or Senior Officer

"Rene Gulliver"  
Signature

CFO  
Official Capacity

<b>Issuer Details</b> Name of Issuer <b>Liberty Health Sciences Inc.</b> <b>(formerly, SecureCom Mobile Inc.)</b>	For Month End  <b>January 31, 2019</b>	Date of Report YY/MM/DD  <b>19/02/13</b>
Issuer Address <b>35 McCaul Street, 2<sup>nd</sup> Floor</b>		
City/Province/Postal Code <b>Toronto, ON M5T 1V7</b>	Issuer Fax No.	Issuer Telephone No.
Contact Name <b>Rene Gulliver</b>	Contact Position <b>CFO</b>	Contact Telephone <b>647-709-0244</b>
Contact Email Address <b>rgulliver@libertyhealthsciences.com</b>	Web Site Address <b><a href="https://libertyhealthsciences.com/">https://libertyhealthsciences.com/</a></b>	